Summary: potential of interleukin-2 for the therapy of cancer

Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ.

Cancer research·1992

The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma.

Cancer research·1992

Nongranular proteolytic enzymes of rat IL-2-activated natural killer cells. I. Subcellular localization and functional role.

Journal of immunology (Baltimore, Md. : 1950)·1992

Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells.

International journal of cancer·1992

Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.

Journal of immunology (Baltimore, Md. : 1950)·1992

Tissue distribution of adoptively transferred adherent LAK cells: role of the route of administration.

Natural immunity·1992

Phase II evaluation of recombinant gamma-interferon in patients with advanced pancreatic carcinoma: a Southwest Oncology Group study.

Journal of biological response modifiers·1990

A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study.

Journal of biological response modifiers·1990

Priming effect of orally administered muramyl dipeptide on induction of endogenous tumor necrosis factor.

Journal of biological response modifiers·1990

Recombinant alpha-interferon enhances tumor targeting of an antimelanoma monoclonal antibody in vivo.

Journal of biological response modifiers·1990

Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.

Journal of biological response modifiers·1990

Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alpha 2a: clinical effects.

Journal of biological response modifiers·1990

Trial designs for assessing induction, maintenance and other treatment effects on a continuous endpoint.

Journal of biopharmaceutical statistics·2026

Direct Oral Anticoagulant Plus Single Versus Dual Antiplatelet Therapy After Carotid Artery Stenting: A Multicenter Propensity-Matched Cohort Study.

Neurosurgery·2026

First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study.

Future oncology (London, England)·2026

Cannabis Assessment in Oncology Patients - Evaluation Survey: Understanding Usage Patterns in a Rural Radiation Cohort in Kentucky.

The oncologist·2026

Spontaneous Regression of Vitreoretinal Lymphoma Lesions: Case Series and Literature Review.

Ocular immunology and inflammation·2026

Blockade of the PD-1 / PD-L1 Axis Exacerbates Chronic Nocardia Brasiliensis Infection by Disrupting Bacterial Immune Containment in BALB/c Mice.

Immunological investigations·2026

Related Experiment Videos

Summary: potential of interleukin-2 for the therapy of cancer

Related Concept Videos

Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ.

The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma.

Nongranular proteolytic enzymes of rat IL-2-activated natural killer cells. I. Subcellular localization and functional role.

Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells.

Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.

Tissue distribution of adoptively transferred adherent LAK cells: role of the route of administration.

Phase II evaluation of recombinant gamma-interferon in patients with advanced pancreatic carcinoma: a Southwest Oncology Group study.

A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study.

Priming effect of orally administered muramyl dipeptide on induction of endogenous tumor necrosis factor.

Recombinant alpha-interferon enhances tumor targeting of an antimelanoma monoclonal antibody in vivo.

Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.

Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alpha 2a: clinical effects.

Trial designs for assessing induction, maintenance and other treatment effects on a continuous endpoint.

Direct Oral Anticoagulant Plus Single Versus Dual Antiplatelet Therapy After Carotid Artery Stenting: A Multicenter Propensity-Matched Cohort Study.

First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study.

Cannabis Assessment in Oncology Patients - Evaluation Survey: Understanding Usage Patterns in a Rural Radiation Cohort in Kentucky.

Spontaneous Regression of Vitreoretinal Lymphoma Lesions: Case Series and Literature Review.

Blockade of the PD-1 / PD-L1 Axis Exacerbates Chronic Nocardia Brasiliensis Infection by Disrupting Bacterial Immune Containment in BALB/c Mice.

Related Experiment Videos

Summary: potential of interleukin-2 for the therapy of cancer

Related Concept Videos

Related Articles